PRLD · Prelude Therapeutics Inc · Executive Compensation
$3.88
+0.18 (+4.86%)
At close · Oct 27
Return incl. dividend (before tax)
Q3 2025 earnings call transcript
Market Cap
$295.27M
Shares
79.80M
Volume · Oct 27
277.22K
Avg daily vol (3M)
518.04K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Krishna Vaddi | Chief Executive Officer | $1,348,000 |
| Bryant D. Lim | Chief Legal Officer, Corporate Secretary, and Chief Financial Officer | $847,397 |
| Peggy Scherle | Ph. D. Chief Scientific Officer | $819,729 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Krishna Vaddi | Chief Executive Officer | $2,327,471 |
| Jane Huang | President and Chief Medical Officer | $1,438,904 |
| Bryant D. Lim | Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer | $1,202,912 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Krishna Vaddi | Chief Executive Officer | $2,641,789 |
| Jane Huang | President and Chief Medical Officer | $1,654,662 |
| Bryant D. Lim | Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer | $1,614,766 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Krishna Vaddi | Chief Executive Officer | $3,304,152 |
| Jane Huang | President and Chief Medical Officer | $2,920,215 |
| Peggy Scherle | Chief Scientific Officer | $1,630,482 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Krishna Vaddi | Chief Executive Officer | $7,042,814 |
| Brian Piper | M.B.A Former Chief Financial Officer | $2,908,023 |
| Peggy Scherle | Chief Scientific Officer | $2,641,799 |
| Andrew P. Combs | EVP and Head of Chemistry | $2,631,289 |
| Jane Huang | President and Chief Medical Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Krishna Vaddi | Ph.D.^(^^3)^ Chief Executive Officer | $11,632,464 |
| Christopher Pierce | M.B.A. Executive Vice President andChief of Business Operations | $3,930,865 |
| Deborah Morosini | Executive Vice President andChief of Clinical Affairs | $3,921,302 |
| Peggy Scherle | Chief Scientific Officer | $2,690,241 |
| Andrew P. Combs | EVP and Head of Chemistry | $2,016,063 |
| Brian Piper | M.B.A Former Chief Financial Officer | $1,961,340 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Krishna Vaddi | Chief Executive Officer | $2,079,400 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Charles Q. Morris, M.D. | Chief Medical Officer | Appointed | 2026-04-15 |
| Jane Huang, M.D. | President and Chief Medical Officer | Resigned | 2025-11-04 |
| Katina Dorton | Class III director | Appointed | 2025-10-17 |
| Mardi Dier | Class III member of the Board of Directors | Resigned | 2025-10-17 |
| Paul Scherer, M.D. | Class III director | Appointed | 2025-06-13 |
| Bryant D. Lim | permanent Chief Financial Officer | Appointed | 2025-02-05 |
| Bryant D. Lim | interim Chief Financial Officer | Appointed | 2024-04-10 |
Leadership
- Krishna Vaddi CEO, Board Member
- Bryant D. Lim CFO
- Julian C. Baker Board Member
- Katina Dorton Board Member
- Martin Babler Board Member
- Paul Scherer, M.D. Board Member